THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to ...
CEO Michael S. Exton stated, "When we entered 2025, if you recall, we're still in the early days of our strategic pivot to being an R&D-focused company. And now in the second half of the year, I can ...
Coiante provided updated guidance: "We're lowering our operating expense projections for the year. Total operating expenses are now expected to be in the range of $105 million to $115 million from ...
THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback